Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00849017
First received: February 19, 2009
Last updated: May 29, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Biological: albiglutide
Biological: albiglutide uptitration
Biological: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    Glycated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. The analysis was performed using an Analysis of Covariance (ANCOVA) model with treatment group, region, history of prior myocardial infarction (yes versus no), and age category (<65 years versus ≥65 years) as factors and Baseline HbA1c as a continuous covariate. The last observation carried forward (LOCF) method was used to impute missing post-BL HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values.


Secondary Outcome Measures:
  • Change From Baseline in HbA1c at Weeks 104 and 156 [ Time Frame: Baseline and Weeks 104 and 156 ] [ Designated as safety issue: No ]
    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.

  • Time to Hyperglycemia Rescue [ Time Frame: From the start of study medication until the end of the treatment (up to Week 156) ] [ Designated as safety issue: No ]
    Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and <Week 4; FPG >=250 mg/dL between >=Week 4 and <Week 12; HbA1c >=8.5% and a <=0.5% reduction from Baseline between >=Week 12 and <Week 24; HbA1c >=8.5% between >=Week 24 and <Week 48; HbA1c >=8.0% between >= Week 48 and <Week 156. Participants could have been rescued at any time on or after Week 2. Time to hyperglycemia rescue is defined as the time between the date of the first dose of study medication and the date of hyperglycemia rescue plus 1 day, or the time between the date of the first dose of study medication and the date of the last visit during the active treatment period plus 1 day for participants not requiring rescue. This time was divided by 7 to express the result in weeks.

  • Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline weight + prior myocardial infarction history + age category + region + current antidiabetic therapy.

  • Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156 [ Time Frame: Baseline and Week 156 ] [ Designated as safety issue: No ]
    The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline FPG minus the Baseline FPG.

  • Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) were assessed.

  • Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156 [ Time Frame: Week 156 ] [ Designated as safety issue: No ]
    The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) were assessed.

  • Change From Baseline in Body Weight at Week 52 [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + prior myocardial infarction history + age category + region + current antidiabetic therapy.

  • Change From Baseline in Body Weight at Week 156 [ Time Frame: Baseline and Week 156 ] [ Designated as safety issue: No ]
    The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight.

  • Change From Baseline in Postprandial Blood Glucose Profile Parameter-4 Hour C-peptide AUC [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    Changes from Baseline at Week 52 in postprandial parameters after a mixed-meal (MM) tolerance test were analyzed. Post prandial blood glucose parameter analyzed was 4 hour c-peptide AUC. The AUC was determined using the trapezoidal method using measurements until 4 hours following the meal. The standardized AUC is the total AUC divided by elapsed time. Those parameters were analyzed analogous to the primary endpoint using an ANCOVA model with treatment group as a factor, and corresponding Baseline postprandial profile as a continuous covariate. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.

  • Change From Baseline in Postprandial Blood Glucose Profile Parameter- 4 Hour Blood Glucose AUC [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    Changes from Baseline at Week 52 in postprandial parameters after a mixed-meal (MM) tolerance test were analyzed. Post prandial blood glucose parameter analyzed was: 4 hour blood glucose area under urve AUC The AUC was determined using the trapezoidal method using measurements until 4 hours following the meal. The standardized AUC is the total AUC divided by elapsed time. Those parameters were analyzed analogous to the primary endpoint using an ANCOVA model with treatment group as a factor, and corresponding Baseline postprandial profile as a continuous covariate. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.

  • Change From Baseline in Postprandial Blood Glucose Profile Parameters-4 Hour Insulin AUC and 4 Hour Proinsulin AUC [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    Changes from Baseline at Week 52 in postprandial parameters after a mixed-meal (MM) tolerance test were analyzed. Post prandial blood glucose parameters analyzed were: 4-hour insulin AUC (4 hr Ins AUC), and 4-hour proinsulin AUC (4 hr pro-Ins AUC). The AUC was determined using the trapezoidal method using measurements until 4 hours following the meal. The standardized AUC is the total AUC divided by elapsed time. Those parameters were analyzed analogous to the primary endpoint using an ANCOVA model with treatment group as a factor, and corresponding Baseline postprandial profile as a continuous covariate. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed.

  • Albiglutide Plasma Concentration at Weeks 8 and 24 [ Time Frame: Weeks 8 and 24 ] [ Designated as safety issue: No ]
    Albiglutide plasma concentration data was analyzed at Week 8 pre-dose, Week 8 post dose, Week 24 pre-dose and Week 24 post-dose. All participants who received albiglutide were initiated on a 30mg weekly dosing regimen; however, beginning at Week 12, participants in the albiglutide 50 mg treatment group were uptitrated to receive albiglutide 50 mg for the remainder of the study.


Enrollment: 309
Study Start Date: January 2009
Study Completion Date: January 2013
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: albiglutide
albiglutide weekly injection
Biological: albiglutide
albiglutide weekly injection
Placebo Comparator: placebo
albiglutide matching placebo
Biological: placebo
matching albiglutide placebo weekly injection
Experimental: albiglutide up-titration
albiglutide weekly injection uptitration at week 12
Biological: albiglutide uptitration
albiglutide uptitration at week 12

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • type 2 diabetes
  • BMI 20-45kg/m2 inclusive

Exclusion Criteria:

  • females who are pregnant, lactating, or <6 weeks post-partum
  • CHF NYHA class III-IV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00849017

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Alabaster, Alabama, United States, 35007
GSK Investigational Site
Birmingham, Alabama, United States, 35235
GSK Investigational Site
Birmingham, Alabama, United States, 35242
GSK Investigational Site
Dothan, Alabama, United States, 36301
United States, Arizona
GSK Investigational Site
Chandler, Arizona, United States, 85225
GSK Investigational Site
Gilbert, Arizona, United States, 85295
GSK Investigational Site
Green Valley, Arizona, United States, 85614
GSK Investigational Site
Phoenix, Arizona, United States, 85051
GSK Investigational Site
Tucson, Arizona, United States, 85745
United States, Arkansas
GSK Investigational Site
Bull Shoals, Arkansas, United States, 72619
GSK Investigational Site
Hot Springs, Arkansas, United States, 71913
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
GSK Investigational Site
Searcy, Arkansas, United States, 72143
United States, California
GSK Investigational Site
Carmichael, California, United States, 95608
GSK Investigational Site
Chula Vista, California, United States, 91910
GSK Investigational Site
Foothill Ranch, California, United States, 92610
GSK Investigational Site
Fresno, California, United States, 93720
GSK Investigational Site
Huntington Beach, California, United States, 92646
GSK Investigational Site
Huntington Beach, California, United States, 92648
GSK Investigational Site
Indio, California, United States, 92201
GSK Investigational Site
Irvine, California, United States, 92618
GSK Investigational Site
Lakewood, California, United States, 90712
GSK Investigational Site
Long Beach, California, United States, 90806
GSK Investigational Site
Los Alamitos, California, United States, 90720
GSK Investigational Site
Los Angeles, California, United States, 90022
GSK Investigational Site
Los Angeles, California, United States, 90017
GSK Investigational Site
Los Angeles, California, United States, 90025
GSK Investigational Site
Mission Viejo, California, United States, 92691
GSK Investigational Site
Northridge, California, United States, 91325
GSK Investigational Site
Palm Desert, California, United States, 92260
GSK Investigational Site
Pasadena, California, United States, 91105
GSK Investigational Site
Riverside, California, United States, 92506
GSK Investigational Site
Sacramento, California, United States, 95825
GSK Investigational Site
San Diego, California, United States, 92177
GSK Investigational Site
San Diego, California, United States, 92128
GSK Investigational Site
San Diego, California, United States, 92117
GSK Investigational Site
San Diego, California, United States, 92120
GSK Investigational Site
Santa Ana, California, United States, 92701
GSK Investigational Site
Satna Monica, California, United States, 90404
GSK Investigational Site
Spring Valley, California, United States, 91978
GSK Investigational Site
Tarzana, California, United States, 91356
GSK Investigational Site
Torrance, California, United States, 90503
GSK Investigational Site
Victorville, California, United States, 92395
GSK Investigational Site
Vista, California, United States, 92083
GSK Investigational Site
Walnut Creek, California, United States, 94598
GSK Investigational Site
West Hills, California, United States, 91307
United States, Colorado
GSK Investigational Site
Arvada, Colorado, United States, 80005
United States, Connecticut
GSK Investigational Site
New Britain, Connecticut, United States, 06050
United States, Delaware
GSK Investigational Site
Middletown, Delaware, United States, 19709
United States, Florida
GSK Investigational Site
Clearwater, Florida, United States, 33756
GSK Investigational Site
Cocoa, Florida, United States, 32927
GSK Investigational Site
Cutler Bay, Florida, United States, 33189
GSK Investigational Site
Deerfield Beach, Florida, United States, 33442
GSK Investigational Site
Delray Beach, Florida, United States, 33445
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33316
GSK Investigational Site
Hallandale Beach, Florida, United States, 33009
GSK Investigational Site
Hialeah, Florida, United States, 33012
GSK Investigational Site
Hollywood, Florida, United States, 33023
GSK Investigational Site
Lauderdale Lakes, Florida, United States, 33319
GSK Investigational Site
Marianna, Florida, United States, 32446
GSK Investigational Site
Miami, Florida, United States, 33156
GSK Investigational Site
Ocala, Florida, United States, 34471
GSK Investigational Site
Orlando, Florida, United States, 32822
GSK Investigational Site
Ormond Beach, Florida, United States, 32174
GSK Investigational Site
Oviedo, Florida, United States, 32765
GSK Investigational Site
Panama City, Florida, United States, 32401
GSK Investigational Site
Pembroke Pines, Florida, United States, 33027
GSK Investigational Site
Pembroke Pines, Florida, United States, 33026
GSK Investigational Site
Plantation, Florida, United States, 33317
GSK Investigational Site
St. Cloud, Florida, United States, 34769
GSK Investigational Site
West Palm Beach, Florida, United States, 33401
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30312
GSK Investigational Site
Atlanta, Georgia, United States, 30338
GSK Investigational Site
Atlanta, Georgia, United States, 30342
GSK Investigational Site
Atlanta, Georgia, United States, 30308
GSK Investigational Site
Blue Ridge, Georgia, United States, 30513
GSK Investigational Site
Columbus, Georgia, United States, 31904
GSK Investigational Site
Decatur, Georgia, United States, 30032
GSK Investigational Site
Savannah, Georgia, United States, 31419
GSK Investigational Site
Savannah, Georgia, United States, 31406
GSK Investigational Site
Snellville, Georgia, United States, 30078
GSK Investigational Site
Tucker, Georgia, United States, 30084
United States, Hawaii
GSK Investigational Site
Honolulu, Hawaii, United States, 96814
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
United States, Idaho
GSK Investigational Site
Idaho Falls, Idaho, United States, 83404
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60607
GSK Investigational Site
Evergreen Park, Illinois, United States, 60805
GSK Investigational Site
La Grange, Illinois, United States, 60525
GSK Investigational Site
Naperville, Illinois, United States, 60564
GSK Investigational Site
Peoria, Illinois, United States, 61602
United States, Indiana
GSK Investigational Site
Avon, Indiana, United States, 46123
GSK Investigational Site
Evansville, Indiana, United States, 47714
GSK Investigational Site
Indianapolis, Indiana, United States, 46254
GSK Investigational Site
La Porte, Indiana, United States, 46350
GSK Investigational Site
South Bend, Indiana, United States, 46614
United States, Iowa
GSK Investigational Site
Council Bluffs, Iowa, United States, 51501
GSK Investigational Site
Dubuque, Iowa, United States, 52001
GSK Investigational Site
Iowa City, Iowa, United States, 52243
GSK Investigational Site
Waterloo, Iowa, United States, 50701
United States, Kansas
GSK Investigational Site
Arkansas City, Kansas, United States, 67005
GSK Investigational Site
Newton, Kansas, United States, 67114
GSK Investigational Site
Overland Park, Kansas, United States, 66211
GSK Investigational Site
Topeka, Kansas, United States, 66606
United States, Kentucky
GSK Investigational Site
Crescent Springs, Kentucky, United States, 41017
GSK Investigational Site
Lexington, Kentucky, United States, 40504
GSK Investigational Site
Madisonville, Kentucky, United States, 42431
GSK Investigational Site
Paducah, Kentucky, United States, 42003
United States, Louisiana
GSK Investigational Site
Covington, Louisiana, United States, 70433
GSK Investigational Site
Lake Charles, Louisiana, United States, 70601
GSK Investigational Site
Shreveport, Louisiana, United States, 71101
GSK Investigational Site
Shreveport, Louisiana, United States, 71115
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21237-3998
GSK Investigational Site
Oxon Hill, Maryland, United States, 20745
United States, Massachusetts
GSK Investigational Site
Haverhill, Massachusetts, United States, 01830
United States, Michigan
GSK Investigational Site
Bay City, Michigan, United States, 48708
GSK Investigational Site
Benzonia, Michigan, United States, 49616
GSK Investigational Site
Dearborn, Michigan, United States, 48124
GSK Investigational Site
Interlochen, Michigan, United States, 49643
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
GSK Investigational Site
Kalamazoo, Michigan, United States, 49048
GSK Investigational Site
St Clair Shores, Michigan, United States, 48081
United States, Mississippi
GSK Investigational Site
Picayune, Mississippi, United States, 39466
GSK Investigational Site
Rolling Fork, Mississippi, United States, 39159
United States, Missouri
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
GSK Investigational Site
Jefferson City, Missouri, United States, 65109
GSK Investigational Site
Kansas City, Missouri, United States, 64111
GSK Investigational Site
Springfield, Missouri, United States, 65807
GSK Investigational Site
St. Louis, Missouri, United States, 63141
GSK Investigational Site
West Plains, Missouri, United States, 65775
United States, Montana
GSK Investigational Site
Great Falls, Montana, United States, 59405
United States, Nebraska
GSK Investigational Site
Broken Bow, Nebraska, United States, 68822
GSK Investigational Site
Lincoln, Nebraska, United States, 68516
GSK Investigational Site
Omaha, Nebraska, United States, 68124
GSK Investigational Site
Omaha, Nebraska, United States, 68131
GSK Investigational Site
Omaha, Nebraska, United States, 68134
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
GSK Investigational Site
Las Vegas, Nevada, United States, 89128
GSK Investigational Site
Las Vegas, Nevada, United States, 89103
United States, New Jersey
GSK Investigational Site
Berlin, New Jersey, United States, 08009
GSK Investigational Site
Elizabeth, New Jersey, United States, 07202
GSK Investigational Site
Haddon Heights, New Jersey, United States, 08035
GSK Investigational Site
Hainesport, New Jersey, United States, 08036
GSK Investigational Site
Stratford, New Jersey, United States, 08084
United States, New York
GSK Investigational Site
North Massapequa, New York, United States, 11758
United States, North Carolina
GSK Investigational Site
Asheville, North Carolina, United States, 28803
GSK Investigational Site
Burlington, North Carolina, United States, 27215
GSK Investigational Site
Calabash, North Carolina, United States, 28467
GSK Investigational Site
Chadbourn, North Carolina, United States, 28431
GSK Investigational Site
Fayetteville, North Carolina, United States, 28304
GSK Investigational Site
Greensboro, North Carolina, United States, 27455
GSK Investigational Site
Hickory, North Carolina, United States, 28601
GSK Investigational Site
Lenoir, North Carolina, United States, 28645
GSK Investigational Site
Mint Hill, North Carolina, United States, 28227
GSK Investigational Site
Morehead City, North Carolina, United States, 28557
GSK Investigational Site
Shelby, North Carolina, United States, 28150
GSK Investigational Site
Tabor City, North Carolina, United States, 28463
United States, Ohio
GSK Investigational Site
Akron, Ohio, United States, 44320
GSK Investigational Site
Canal Fulton, Ohio, United States, 44614
GSK Investigational Site
Cleveland, Ohio, United States, 44122
GSK Investigational Site
Columbus, Ohio, United States, 43213
GSK Investigational Site
Dayton, Ohio, United States, 45439
GSK Investigational Site
Dayton, Ohio, United States, 45432
GSK Investigational Site
Kettering, Ohio, United States, 45429
GSK Investigational Site
Mason, Ohio, United States, 45040
GSK Investigational Site
Maumee, Ohio, United States, 43537-9402
GSK Investigational Site
Thornville, Ohio, United States, 43076
GSK Investigational Site
Zanesville, Ohio, United States, 43701
United States, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73103
GSK Investigational Site
Tulsa, Oklahoma, United States, 74104
GSK Investigational Site
Tulsa, Oklahoma, United States, 74136
United States, Oregon
GSK Investigational Site
Ashland, Oregon, United States, 97520
United States, Pennsylvania
GSK Investigational Site
Bensalem, Pennsylvania, United States, 19020
GSK Investigational Site
Downington, Pennsylvania, United States, 19335
GSK Investigational Site
Harrisburg, Pennsylvania, United States, 17112
GSK Investigational Site
Lansdale, Pennsylvania, United States, 19446
GSK Investigational Site
Melrose Park, Pennsylvania, United States, 19027
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
GSK Investigational Site
Tipton, Pennsylvania, United States, 16684
GSK Investigational Site
Uniontown, Pennsylvania, United States, 15401
United States, Rhode Island
GSK Investigational Site
East Providence, Rhode Island, United States, 02914
United States, South Carolina
GSK Investigational Site
Columbia, South Carolina, United States, 29201
GSK Investigational Site
Greenville, South Carolina, United States, 29601
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Greer, South Carolina, United States, 29651
GSK Investigational Site
Murrells Inlet, South Carolina, United States, 29576
GSK Investigational Site
North Myrtle Beach, South Carolina, United States, 29582
GSK Investigational Site
Orangeburg, South Carolina, United States, 29115
GSK Investigational Site
Simpsonville, South Carolina, United States, 29681
GSK Investigational Site
Taylors, South Carolina, United States, 29687
United States, Tennessee
GSK Investigational Site
Bristol, Tennessee, United States, 37620
GSK Investigational Site
Clarksville, Tennessee, United States, 37043
GSK Investigational Site
Columbia, Tennessee, United States, 38401
GSK Investigational Site
Crossville, Tennessee, United States, 38555
GSK Investigational Site
Johnson City, Tennessee, United States, 37604
GSK Investigational Site
McKenzie, Tennessee, United States, 38201
GSK Investigational Site
Nashville, Tennessee, United States, 37203
GSK Investigational Site
Tullahoma, Tennessee, United States, 37388
United States, Texas
GSK Investigational Site
Arlington, Texas, United States, 76012
GSK Investigational Site
Cleburne, Texas, United States, 76033
GSK Investigational Site
Corpus Christi, Texas, United States, 78414
GSK Investigational Site
Dallas, Texas, United States, 75230
GSK Investigational Site
Dallas, Texas, United States, 75235
GSK Investigational Site
Dallas, Texas, United States, 75251
GSK Investigational Site
Dallas, Texas, United States, 75224
GSK Investigational Site
Deer Park, Texas, United States, 77536
GSK Investigational Site
El Paso, Texas, United States, 79925
GSK Investigational Site
Fort Worth, Texas, United States, 76104
GSK Investigational Site
Houston, Texas, United States, 77024
GSK Investigational Site
Houston, Texas, United States, 77070
GSK Investigational Site
Houston, Texas, United States, 77058
GSK Investigational Site
Houston, Texas, United States, 77034
GSK Investigational Site
Houston, Texas, United States, 77055
GSK Investigational Site
Houston, Texas, United States, 77036
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Houston, Texas, United States, 77074
GSK Investigational Site
Hurst, Texas, United States, 76054
GSK Investigational Site
Katy, Texas, United States, 77450
GSK Investigational Site
Lewisville, Texas, United States, 75067
GSK Investigational Site
Midland, Texas, United States, 79705
GSK Investigational Site
Odessa, Texas, United States, 79761
GSK Investigational Site
San Antonio, Texas, United States, 78229-4801
GSK Investigational Site
San Antonio, Texas, United States, 78229
GSK Investigational Site
San Antonio, Texas, United States, 78215
GSK Investigational Site
San Antonio, Texas, United States, 78224
GSK Investigational Site
San Antonio, Texas, United States, 78218
GSK Investigational Site
San Antonio, Texas, United States, 78258
GSK Investigational Site
Schertz, Texas, United States, 78154
GSK Investigational Site
Sugar Land, Texas, United States, 77479
GSK Investigational Site
Sugarland, Texas, United States, 77479
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84102
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
GSK Investigational Site
Salt Lake City, Utah, United States, 84120
GSK Investigational Site
West Jordan, Utah, United States, 84088
GSK Investigational Site
West Valley City, Utah, United States, 84120
United States, Vermont
GSK Investigational Site
South Burlington, Vermont, United States, 05403
United States, Virginia
GSK Investigational Site
Burke, Virginia, United States, 22015
GSK Investigational Site
Manassas, Virginia, United States, 20110
GSK Investigational Site
Norfolk, Virginia, United States, 23502
GSK Investigational Site
Suffolk, Virginia, United States, 23434
GSK Investigational Site
Virgina Beach, Virginia, United States, 23455
GSK Investigational Site
Weber City, Virginia, United States, 24290
United States, Washington
GSK Investigational Site
Richland, Washington, United States, 99352
GSK Investigational Site
Selah, Washington, United States, 98942
GSK Investigational Site
Spokane, Washington, United States, 99216
United States, West Virginia
GSK Investigational Site
Lewisburg, West Virginia, United States, 24901
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53226
Mexico
GSK Investigational Site
Tijuana, Baja California Norte, Mexico, 22010
GSK Investigational Site
Pachuca, Hidalgo, Mexico, 42086
GSK Investigational Site
Zapopan, Jalisco, Mexico, 45200
GSK Investigational Site
Morelia, Michoacán, Mexico, C.P. 58249
GSK Investigational Site
Merida, Yucatán, Mexico, 97000
GSK Investigational Site
Cuernavaca, Mexico, 62250
GSK Investigational Site
Distrito Federal, Mexico, 06700
GSK Investigational Site
Guadalajara, Mexico, 44680
GSK Investigational Site
Guadalajara, Mexico, 44600
GSK Investigational Site
Mexico City, Mexico, 03300
GSK Investigational Site
Mexico City, Mexico, 11570
GSK Investigational Site
Nezahualcoyotl, Mexico, 57170
GSK Investigational Site
Puebla, Mexico, 72190
GSK Investigational Site
Torreón, Mexico, 27000
South Africa
GSK Investigational Site
Parow, South Africa, 7505
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00849017     History of Changes
Other Study ID Numbers: 112756
Study First Received: February 19, 2009
Results First Received: April 24, 2014
Last Updated: May 29, 2014
Health Authority: South Africa: Medicines Control Council
Mexico: Ministry of Health
United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
placebo
albiglutide
monotherapy
diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 24, 2014